The DOI matches its Crossref record; 284 of the 284 references it cites were found in a registry or an index.
50 years of hurdles and hope in anxiolytic drug discovery
Open accessAbstract
Anxiety disorders are the most prevalent group of psychiatric diseases, and have high personal and societal costs. The search for novel pharmacological treatments for these conditions is driven by the growing medical need to improve on the effectiveness and the side effect profile of existing drugs. A huge volume of data has been generated by anxiolytic drug discovery studies, which has led to the progression of numerous new molecules into clinical trials. However, the clinical outcome of these efforts has been disappointing, as promising results with novel agents in rodent studies have very rarely translated into effectiveness in humans. Here, we analyse the major trends from preclinical studies over the past 50 years conducted in the search for new drugs beyond those that target the prototypical anxiety-associated GABA (γ-aminobutyric acid)–benzodiazepine system, which have focused most intensively on the serotonin, neuropeptide, glutamate and endocannabinoid systems. We highlight various key issues that may have hampered progress in the field, and offer recommendations for how anxiolytic drug discovery can be more effective in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Lesch, K.-P., Bengel, D., Heils, A., Sabol, S. Z., Greenberg, B. D., Petri, S., Benjamin, J., Müller, C. R., Hamer, D. H., & Murphy, D. L. (1996) · Science · doi:10.1126/science.274.5292.1527 · Cited by 5,162
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965
VALE, W., SPIESS, J., RIVIER, C., & RIVIER, J. (1982) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198205000-00013 · Cited by 3,904
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754
The use of a plus-maze to measure anxiety in the mouse
Lister, R. (1987) · Psychopharmacology · doi:10.1007/bf00177912 · Cited by 2,609
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
Grand challenges in global mental health
Collins, P. Y., Patel, V., Joestl, S. S., March, D., Insel, T. R., Daar, A. S., Bordin, I. A., Costello, E. J., Durkin, M., Fairburn, C., et al. (2011) · Nature · doi:10.1038/475027a · Cited by 2,043
Optogenetics in neural systems
Yizhar, O., Fenno, L. E., Davidson, T. J., Mogri, M., & Deisseroth, K. (2011) · Neuron · doi:10.1016/j.neuron.2011.06.004 · Cited by 1,881
The endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728
Genetics of Mouse Behavior: Interactions with Laboratory Environment
Crabbe, J. C., Wahlsten, D., & Dudek, B. C. (1999) · Science · doi:10.1126/science.284.5420.1670 · Cited by 1,666
Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety
Davis, M., Walker, D. L., Miles, L., & Grillon, C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.109 · Cited by 1,513
Crawley, J. N., Belknap, J. K., Collins, A., Crabbe, J. C., Frankel, W., Henderson, N., Hitzemann, R. J., Maxson, S. C., Miner, L. L., Silva, A. J., et al. (1997) · Psychopharmacology · doi:10.1007/s002130050327 · Cited by 1,372
Hall, C. S. (1934) · Journal of Comparative Psychology · doi:10.1037/h0071444 · Cited by 1,347
Caspi, A., Hariri, A. R., Holmes, A., Uher, R., & Moffitt, T. E. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09101452 · Cited by 1,346
Self-citationAmygdala circuitry mediating reversible and bidirectional control of anxiety
Tye, K. M., Prakash, R., Kim, S.-Y., Fenno, L. E., Grosenick, L., Zarabi, H., Thompson, K. R., Gradinaru, V., Ramakrishnan, C., & Deisseroth, K. (2011) · Nature · doi:10.1038/nature09820 · Cited by 1,289
Myers, K. M., & Davis, M. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001939 · Cited by 1,277
The ascent of mouse: advances in modelling human depression and anxiety
Cryan, J. F., & Holmes, A. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1825 · Cited by 1,198
Self-citationSex Differences in Pharmacokinetics and Pharmacodynamics
Soldin, O. P., & Mattison, D. R. (2009) · Clinical Pharmacokinetics · doi:10.2165/00003088-200948030-00001 · Cited by 1,163
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063
Handley, S. L., & Mithani, S. (1984) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00504983 · Cited by 969
Chalmers, D., Lovenberg, T., & De Souza, E. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-10-06340.1995 · Cited by 919
Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor
Ledent, C., Vaugeois, J.-M., Schiffmann, S. N., Pedrazzini, T., Yacoubi, M. E., Vanderhaeghen, J.-J., Costentin, J., Heath, J. K., Vassart, G., & Parmentier, M. (1997) · Nature · doi:10.1038/41771 · Cited by 918
Measuring normal and pathological anxiety-like behaviour in mice: a review
Belzung, C., & Griebel, G. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00291-1 · Cited by 912
Self-citationSerotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult
Gross, C., Zhuang, X., Stark, K., Ramboz, S., Oosting, R., Kirby, L., Santarelli, L., Beck, S., & Hen, R. (2002) · Nature · doi:10.1038/416396a · Cited by 903
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
Gogos, J. A., Morgan, M., Luine, V., Santha, M., Ogawa, S., Pfaff, D., & Karayiorgou, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9991 · Cited by 864
Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor
Ichiki, T., Labosky, P. A., Shiota, C., Okuyama, S., Imagawa, Y., Fogo, A., Niimura, F., Ichikawa, I., Hogan, B. L. M., & lnagami, T. (1995) · Nature · doi:10.1038/377748a0 · Cited by 858
Bale, T. L., Contarino, A., Smith, G. W., Chan, R., Gold, L. H., Sawchenko, P. E., Koob, G. F., Vale, W. W., & Lee, K.-F. (2000) · Nature Genetics · doi:10.1038/74263 · Cited by 849
A simple and reliable conflict procedure for testing anti-anxiety agents
Vogel, J. R., Beer, B., & Clody, D. E. (1971) · Psychopharmacologia · doi:10.1007/bf00403989 · Cited by 841
Automated design of ligands to polypharmacological profiles
Besnard, J., Ruda, G. F., Setola, V., Abecassis, K., Rodriguiz, R. M., Huang, X.-P., Norval, S., Sassano, M. F., Shin, A. I., Webster, L. A., et al. (2012) · Nature · doi:10.1038/nature11691 · Cited by 832
Early-Life Blockade of the 5-HT Transporter Alters Emotional Behavior in Adult Mice
Ansorge, M. S., Zhou, M., Lira, A., Hen, R., & Gingrich, J. A. (2004) · Science · doi:10.1126/science.1101678 · Cited by 817
File, S. E. (1980) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(80)90012-6 · Cited by 815
Serotonin receptor 1A knockout: An animal model of anxiety-related disorder
Ramboz, S., Oosting, R., Amara, D. A., Kung, H. F., Blier, P., Mendelsohn, M., Mann, J. J., Brunner, D., & Hen, R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14476 · Cited by 814
Neuropeptide Transmission in Brain Circuits
van den Pol, A. N. (2012) · Neuron · doi:10.1016/j.neuron.2012.09.014 · Cited by 810
New peptide in the vertebrate CNS reacting with antigastrin antibodies
VANDERHAEGHEN, J. J., SIGNEAU, J. C., & GEPTS, W. (1975) · Nature · doi:10.1038/257604a0 · Cited by 758
Optogenetic investigation of neural circuits underlying brain disease in animal models
Tye, K. M., & Deisseroth, K. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3171 · Cited by 745
Shepherd, J. K., Grewal, S. S., Fletcher, A., Bill, D. J., & Dourish, C. T. (1994) · Psychopharmacology · doi:10.1007/bf02244871 · Cited by 739
Maier, S. F., & Watkins, L. R. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.021 · Cited by 737
Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes
Rudolph, U., & Knoflach, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3502 · Cited by 733
Animal Model of Depression: I. Review of Evidence: Implications for Research
McKinney, W. T. (1969) · Archives of General Psychiatry · doi:10.1001/archpsyc.1969.01740200112015 · Cited by 727
Two brain cholecystokinin receptors: implications for behavioral actions
Moran, T. H., Robinson, P. H., Goldrich, M. S., & McHugh, P. R. (1986) · Brain Research · doi:10.1016/0006-8993(86)91413-7 · Cited by 716
Elevated anxiety and antidepressant-like responses in serotonin 5-HT 1A receptor mutant mice
Heisler, L. K., Chu, H.-M., Brennan, T. J., Danao, J. A., Bajwa, P., Parsons, L. H., & Tecott, L. H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.15049 · Cited by 709
Increased anxiety of mice lacking the serotonin 1A receptor
Parks, C. L., Robinson, P. S., Sibille, E., Shenk, T., & Toth, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10734 · Cited by 691
Genetics of emotional regulation: the role of the serotonin transporter in neural function
Hariri, A. R., & Holmes, A. (2006) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2006.02.011 · Cited by 669
Self-citationAnimal models of anxiety: an ethological perspective
Rodgers, R. J., Cao, B.-J., Dalvi, A., & Holmes, A. (1997) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x1997000300002 · Cited by 645
Self-citationReceptors and antagonists for substance P and related peptides.
Regoli, D., Boudon, A., & Fauchére, J. L. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06810-3 · Cited by 631
Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex
Covington, H. E., Lobo, M. K., Maze, I., Vialou, V., Hyman, J. M., Zaman, S., LaPlant, Q., Mouzon, E., Ghose, S., Tamminga, C. A., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1731-10.2010 · Cited by 621
Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
Vaswani, M., Linda, F. K., & Ramesh, S. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00338-x · Cited by 612
Coste, S. C., Kesterson, R. A., Heldwein, K. A., Stevens, S. L., Heard, A. D., Hollis, J. H., Murray, S. E., Hill, J. K., Pantely, G. A., Hohimer, A. R., et al. (2000) · Nature Genetics · doi:10.1038/74255 · Cited by 590
The Kraepelinian dichotomy – going, going … but still not gone
Craddock, N., & Owen, M. J. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.073429 · Cited by 587
Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues
Crestani, F., Lorez, M., Baer, K., Essrich, C., Benke, D., Laurent, J. P., Belzung, C., Fritschy, J.-M., Lüscher, B., & Mohler, H. (1999) · Nature Neuroscience · doi:10.1038/12207 · Cited by 550
Animal models of anxiety and depression: how are females different?
Palanza, P. (2001) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(01)00010-0 · Cited by 542
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510
Xu, Y.-L., Reinscheid, R. K., Huitron-Resendiz, S., Clark, S. D., Wang, Z., Lin, S. H., Brucher, F. A., Zeng, J., Ly, N. K., Henriksen, S. J., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.08.005 · Cited by 510
Development of lifetime comorbidity in the World Health Organization world mental health surveys
Kessler, R. C., Ormel, J., Petukhova, M., McLaughlin, K. A., Green, J. G., Russo, L. J., Stein, D. J., Zaslavsky, A. M., Aguilar-Gaxiola, S., Alonso, J., et al. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.180 · Cited by 508
Crawley, J. N. (1981) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(81)90007-1 · Cited by 508
Involvement of CB1 cannabinoid receptors in emotional behaviour
Martin, M., Ledent, C., Parmentier, M., Maldonado, R., & Valverde, O. (2002) · Psychopharmacology · doi:10.1007/s00213-001-0946-5 · Cited by 507
Deletion of Crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2
Kishimoto, T., Radulovic, J., Radulovic, M., Lin, C. R., Schrick, C., Hooshmand, F., Hermanson, O., Rosenfeld, M. G., & Spiess, J. (2000) · Nature Genetics · doi:10.1038/74271 · Cited by 502
Behavioral effects of estrogen receptor gene disruption in male mice
Ogawa, S., Lubahn, D. B., Korach, K. S., & Pfaff, D. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.4.1476 · Cited by 498
Griebel, G. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)98597-j · Cited by 488
Self-citationEvaluation of marble-burying behavior as a model of anxiety
Njung'e, K., & Handley, S. L. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90590-x · Cited by 487
Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin
König, M., Zimmer, A. M., Steiner, H., Holmes, P. V., Crawley, J. N., Brownstein, M. J., & Zimmer, A. (1996) · Nature · doi:10.1038/383535a0 · Cited by 484
Stenzel-Poore, M., Heinrichs, S., Rivest, S., Koob, G., & Vale, W. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-05-02579.1994 · Cited by 468
Belzung, C., & Lemoine, M. (2011) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-1-9 · Cited by 438
Animal models of ‘anxiety’: Where next?
Rodgers, R. J. (1997) · Behavioural Pharmacology · doi:10.1097/00008877-199711000-00003 · Cited by 437
The effects of chronic antidepressant treatment in an animal model of anxiety
Bodnoff, S., Suranyi-Cadotte, B., Aitken, D., Quirion, R., & Meaney, M. (1988) · Psychopharmacology · doi:10.1007/bf00181937 · Cited by 437
Dopamine D4 Receptor-Knock-Out Mice Exhibit Reduced Exploration of Novel Stimuli
Dulawa, S. C., Grandy, D. K., Low, M. J., Paulus, M. P., & Geyer, M. A. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-21-09550.1999 · Cited by 431
The comparative efficacy of buspirone and diazepam in the treatment of anxiety
(1979) · American Journal of Psychiatry · doi:10.1176/ajp.136.9.1184 · Cited by 422
Conditioned defensive burying: A new paradigm for the study of anxiolytic agents
Treit, D., Pinel, J. P. J., & Fibiger, H. C. (1981) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(81)90219-7 · Cited by 420
Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders
Holmes, A., Heilig, M., Rupniak, N. M. J., Steckler, T., & Griebel, G. (2003) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2003.09.011 · Cited by 403
Self-citationLira, A., Zhou, M., Castanon, N., Ansorge, M. S., Gordon, J. A., Francis, J. H., Bradley-Moore, M., Lira, J., Underwood, M. D., Arango, V., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00696-6 · Cited by 391
Disability and treatment of specific mental and physical disorders across the world
Ormel, J., Petukhova, M., Chatterji, S., Aguilar-Gaxiola, S., Alonso, J., Angermeyer, M. C., Bromet, E. J., Burger, H., Demyttenaere, K., de Girolamo, G., et al. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.039107 · Cited by 389
Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders
Youdim, M. B. H., & Buccafusco, J. J. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.11.007 · Cited by 380
LANG, R., GUNDLACH, A., & KOFLER, B. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.05.009 · Cited by 376
Bielsky, I. F., Hu, S.-B., Ren, X., Terwilliger, E. F., & Young, L. J. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.031 · Cited by 367
Wellman, C. L., Izquierdo, A., Garrett, J. E., Martin, K. P., Carroll, J., Millstein, R., Lesch, K.-P., Murphy, D. L., & Holmes, A. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4595-06.2007 · Cited by 366
Self-citationNeumeister, A., Normandin, M. D., Pietrzak, R. H., Piomelli, D., Zheng, M. Q., Gujarro-Anton, A., Potenza, M. N., Bailey, C. R., Lin, S. F., Najafzadeh, S., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.61 · Cited by 361
The Serotonin-1A Receptor in Anxiety Disorders
Akimova, E., Lanzenberger, R., & Kasper, S. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.03.012 · Cited by 360
The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety
Haller, J., Bakos, N., Szirmay, M., Ledent, C., & Freund, T. F. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02192.x · Cited by 354
Mombereau, C., Kaupmann, K., Froestl, W., Sansig, G., van der Putten, H., & Cryan, J. F. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300413 · Cited by 350
Altered anxiety‐related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome
Spencer, C. M., Alekseyenko, O., Serysheva, E., Yuva‐Paylor, L. A., & Paylor, R. (2005) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2005.00123.x · Cited by 349
Mood and Anxiety Related Phenotypes in Mice: Characterization Using Behavioral Tests
(2009) · Neuromethods · doi:10.1007/978-1-60761-303-9 · Cited by 349
Davis, M. (1986) · Behavioral Neuroscience · doi:10.1037//0735-7044.100.6.814 · Cited by 343
Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects
Rupprecht, R., Rammes, G., Eser, D., Baghai, T. C., Schüle, C., Nothdurfter, C., Troxler, T., Gentsch, C., Kalkman, H. O., Chaperon, F., et al. (2009) · Science · doi:10.1126/science.1175055 · Cited by 328
Holmes, A., Yang, R. J., Lesch, K.-P., Crawley, J. N., & Murphy, D. L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300266 · Cited by 315
Self-citationGlutamatergic and Dopaminergic Neurons Mediate Anxiogenic and Anxiolytic Effects of CRHR1
Refojo, D., Schweizer, M., Kuehne, C., Ehrenberg, S., Thoeringer, C., Vogl, A. M., Dedic, N., Schumacher, M., von Wolff, G., Avrabos, C., et al. (2011) · Science · doi:10.1126/science.1202107 · Cited by 313
Gartside, S. E., Umbers, V., Hajós, M., & Sharp, T. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb15919.x · Cited by 312
Optical activation of lateral amygdala pyramidal cells instructs associative fear learning
Johansen, J. P., Hamanaka, H., Monfils, M. H., Behnia, R., Deisseroth, K., Blair, H. T., & LeDoux, J. E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002418107 · Cited by 308
Buspirone and diazepam in anxiety: a controlled study.
Rickels, K., Weisman, K., Norstad, N., Singer, M. L., Stoltz, D., Brown, A. S., & Danton, J. (1982) · PubMed · Cited by 308
Gunduz-Cinar, O., MacPherson, K. P., Cinar, R., Gamble-George, J., Sugden, K., Williams, B., Godlewski, G., Ramikie, T. S., Gorka, A. X., Alapafuja, S. O., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.72 · Cited by 307
Self-citationThe Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic
Blanchard, D. C., Griebel, G., & Blanchard, R. J. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01276-7 · Cited by 295
Self-citationHolmes, A. J., Lee, P. H., Hollinshead, M. O., Bakst, L., Roffman, J. L., Smoller, J. W., & Buckner, R. L. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2531-12.2012 · Cited by 293
Self-citationBehavioral characterization of neuropeptide Y knockout mice
Bannon, A. W., Seda, J., Carmouche, M., Francis, J. M., Norman, M. H., Karbon, B., & McCaleb, M. L. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02285-x · Cited by 290
Haller, J., Varga, B., Ledent, C., Barna, I., & Freund, T. F. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03293.x · Cited by 284
Therapeutic potential of neuropeptide Y (NPY) receptor ligands
Brothers, S. P., & Wahlestedt, C. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000100 · Cited by 267
Topol, E. J., Bousser, M.-G., Fox, K. A., Creager, M. A., Despres, J.-P., Easton, J. D., Hamm, C. W., Montalescot, G., Steg, P. G., Pearson, T. A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60935-x · Cited by 266
The elevated T-maze: A new animal model of anxiety and memory
Viana, M. B., Tomaz, C., & Graeff, F. G. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90067-1 · Cited by 264
Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease
Holmes, A. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.006 · Cited by 264
Self-citationIdentification of Glyoxalase-I as a Protein Marker in a Mouse Model of Extremes in Trait Anxiety
Krömer, S. A., Keßler, M. S., Milfay, D., Birg, I. N., Bunck, M., Czibere, L., Panhuysen, M., Pütz, B., Deussing, J. M., Holsboer, F., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0115-05.2005 · Cited by 263
Griebel, G., Stemmelin, J., & Scatton, B. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.032 · Cited by 253
Self-citationGlucocorticoid receptor overexpression in forebrain: A mouse model of increased emotional lability
Wei, Q., Lu, X.-Y., Liu, L., Schafer, G., Shieh, K.-R., Burke, S., Robinson, T. E., Watson, S. J., Seasholtz, A. F., & Akil, H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402208101 · Cited by 248
Köster, A., Montkowski, A., Schulz, S., Stübe, E.-M., Knaudt, K., Jenck, F., Moreau, J.-L., Nothacker, H.-P., Civelli, O., & Reinscheid, R. K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10444 · Cited by 247
Neuroscience, Clinical Evidence, and the Future of Psychiatric Classification in DSM-5
Kupfer, D. J., & Regier, D. A. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11020219 · Cited by 245
Palmiter, R. D., Erickson, J. C., Hollopeter, G., Baraban, S. C., & Schwartz, M. W. (1998) · PubMed · Cited by 242
Haller, J., Varga, B., Ledent, C., & Freund, T. F. (2004) · Behavioural Pharmacology · doi:10.1097/01.fbp.0000135704.56422.40 · Cited by 241
Griebel, G., Belzung, C., Misslin, R., & Vogel, E. (1993) · Behavioural Pharmacology · doi:10.1097/00008877-199312000-00009 · Cited by 239
Self-citationThe effects of chlordiazepoxide and chlorpromazine on a punishment discrimination
Geller, I., Kulak, J. T., & Seifter, J. (1962) · Psychopharmacologia · doi:10.1007/bf00408322 · Cited by 239
Chiu, C.-S., Brickley, S., Jensen, K., Southwell, A., Mckinney, S., Cull-Candy, S., Mody, I., & Lester, H. A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3364-04.2005 · Cited by 238
Mozhui, K., Karlsson, R.-M., Kash, T. L., Ihne, J., Norcross, M., Patel, S., Farrell, M. R., Hill, E. E., Graybeal, C., Martin, K. P., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5017-09.2010 · Cited by 226
Self-citationEndocannabinoid system and mood disorders: Priming a target for new therapies
Micale, V., Di Marzo, V., Sulcova, A., Wotjak, C. T., & Drago, F. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.002 · Cited by 223
Hill, M. N., Kumar, S. A., Filipski, S. B., Iverson, M., Stuhr, K. L., Keith, J. M., Cravatt, B. F., Hillard, C. J., Chattarji, S., & McEwen, B. S. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.90 · Cited by 222
Metabolism and disposition of buspirone
Gammans, R. E., Mayol, R. F., & Labudde, J. A. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90331-1 · Cited by 219
Cannabinoid CB1 Receptor Mediates Fear Extinction via Habituation-Like Processes
Kamprath, K., Marsicano, G., Tang, J., Monory, K., Bisogno, T., Marzo, V. D., Lutz, B., & Wotjak, C. T. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0153-06.2006 · Cited by 217
Schramm, N. L., McDonald, M. P., & Limbird, L. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-13-04875.2001 · Cited by 217
Kash, S. F., Tecott, L. H., Hodge, C., & Baekkeskov, S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1698 · Cited by 216
An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs
Handley, S. L., & McBlane, J. W. (1993) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/1056-8719(93)90063-k · Cited by 214
Overview of Diagnosis and Drug Treatments of Anxiety Disorders
Nutt, D. J. (2005) · CNS Spectrums · doi:10.1017/s1092852900009901 · Cited by 211
Avenevoli, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1603 · Cited by 206
Ross, S. A., Wong, J. Y. F., Clifford, J. J., Kinsella, A., Massalas, J. S., Horne, M. K., Scheffer, I. E., Kola, I., Waddington, J. L., Berkovic, S. F., et al. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-17-06431.2000 · Cited by 204
Earnheart, J. C., Schweizer, C., Crestani, F., Iwasato, T., Itohara, S., Mohler, H., & Lüscher, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3609-06.2007 · Cited by 203
Holmes, A., Kinney, J. W., Wrenn, C. C., Li, Q., Yang, R. J., Ma, L., Vishwanath, J., Saavedra, M. C., Innerfield, C. E., Jacoby, A. S., et al. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300164 · Cited by 202
Self-citationLandgraf, R., Keßler, M. S., Bunck, M., Murgatroyd, C., Spengler, D., Zimbelmann, M., Nußbaumer, M., Czibere, L., Turck, C. W., Singewald, N., et al. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2006.07.003 · Cited by 199
Targeted gene mutation approaches to the study of anxiety-like behavior in mice
Holmes, A. (2001) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(01)00012-4 · Cited by 197
Self-citationClinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety
Kent, J. M., Coplan, J. D., & Gorman, J. M. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00210-8 · Cited by 196
Sustained Long Term Potentiation and Anxiety in Mice Lacking theMas Protooncogene
Walther, T., Balschun, D., Voigt, J.-P., Fink, H., Zuschratter, W., Birchmeier, C., Ganten, D., & Bader, M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.19.11867 · Cited by 196
Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?
Griebel, G., & Holsboer, F. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3702 · Cited by 194
Self-citationRichardson-Jones, J. W., Craige, C. P., Nguyen, T. H., Kung, H. F., Gardier, A. M., Dranovsky, A., David, D. J., Guiard, B. P., Beck, S. G., Hen, R., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5836-10.2011 · Cited by 192
Effects of transgenic overproduction of CRH on anxiety‐like behaviour
Van Gaalen, M. M., Stenzel‐Poore, M. P., Holsboer, F., & Steckler, T. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02040.x · Cited by 189
España, J., Giménez-Llort, L., Valero, J., Miñano, A., Rábano, A., Rodriguez-Alvarez, J., LaFerla, F. M., & Saura, C. A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.06.015 · Cited by 187
Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications
Richardson, R., Ledgerwood, L., & Cranney, J. (2004) · Learning & Memory · doi:10.1101/lm.78204 · Cited by 185
(2007) · PubMed · Cited by 184
Sibille, E., Pavlides, C., Benke, D., & Toth, M. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-08-02758.2000 · Cited by 183
Pharmacological treatment of PTSD – Established and new approaches
Steckler, T., & Risbrough, V. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.06.012 · Cited by 182
Baseline exploratory activity predicts anxiolytic responsiveness to diazepam in five mouse strains
Crawley, J. N., & Davis, L. G. (1982) · Brain Research Bulletin · doi:10.1016/0361-9230(82)90087-9 · Cited by 182
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal, J. H., Mathew, S. J., DʼSouza, D. C., Garakani, A., Gunduz-Bruce, H., & Charney, D. S. (2010) · CNS Drugs · doi:10.2165/11533230-000000000-00000 · Cited by 180
Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder
Dunayevich, E., Erickson, J., Levine, L., Landbloom, R., Schoepp, D. D., & Tollefson, G. D. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301531 · Cited by 179
Moreira, F. A., & Wotjak, C. T. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_16 · Cited by 177
Postnatal development of a GABA deficit and disturbance of neural functions in mice lacking GAD65
Stork, O., Ji, F.-Y., Kaneko, K., Stork, S., Yoshinobu, Y., Moriya, T., Shibata, S., & Obata, K. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02206-x · Cited by 177
Stein, D. J., Ahokas, A. A., & de Bodinat, C. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318184ff5b · Cited by 174
Is There a Future for Neuropeptide Receptor Ligands in the Treatment of Anxiety Disorders?
Griebel, G. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00041-2 · Cited by 171
Self-citationIncreased Fear Response to Contextual Cues in Mice Lacking the 5-HT1A Receptor
Klemenhagen, K. C., Gordon, J. A., David, D. J., Hen, R., & Gross, C. T. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300774 · Cited by 167
Neuropeptide Y and posttraumatic stress disorder
Sah, R., & Geracioti, T. D. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.101 · Cited by 166
Dubreucq, S., Matias, I., Cardinal, P., Häring, M., Lutz, B., Marsicano, G., & Chaouloff, F. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.36 · Cited by 159
Maccarrone, M., Valverde, O., Barbaccia, M. L., Castañé, A., Maldonado, R. J., Ledent, C. A., Parmentier, M., & Finazzi‐Agrò, A. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.01957.x · Cited by 158
Suppression of conditioning to ambiguous cues by pharmacogenetic inhibition of the dentate gyrus
Tsetsenis, T., Ma, X.-H., Iacono, L. L., Beck, S. G., & Gross, C. T. (2007) · Nature Neuroscience · doi:10.1038/nn1919 · Cited by 153
Altered anxiety and weight gain in corticotropin-releasing hormone-binding protein-deficient mice
Karolyi, I. J., Burrows, H. L., Ramesh, T., Nakajima, M., Lesh, J., Seong, E., Camper, S. A., & Seasholtz, A. F. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11595 · Cited by 153
Behavioral and neurochemical changes following predatory stress in mice
Belzung, C., El‐Hage, W., Moindrot, N., & Griebel, G. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00072-7 · Cited by 150
Self-citationAnxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149
Zhang, J., Huang, X., Ye, M.-L., Luo, C., Wu, H., Hu, Y. F., Zhou, Q., Wu, D., Zhu, L., & Zhu, D. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.5880-09.2010 · Cited by 148
Individual differences in recovery from traumatic fear
Holmes, A., & Singewald, N. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.11.003 · Cited by 147
Self-citationAzapirones for generalized anxiety disorder
Chessick, C. A., Allen, M. H., Thase, M. E., Batista Miralha da Cunha, A. A., Kapczinski, F., Silva de Lima, M., & dos Santos Souza, J. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006115 · Cited by 144
Nakamura, E., Kadomatsu, K., Yuasa, S., Muramatsu, H., Mamiya, T., NABESHIMA, T., Fan, Q., Ishiguro, K., Igakura, T., Matsubara, S., et al. (1998) · Genes to Cells · doi:10.1046/j.1365-2443.1998.00231.x · Cited by 144
Blanchard, R. J. (2008) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(07)x0001-8 · Cited by 142
The WHO World Mental Health (WMH) Surveys
Aguilar‐Gaxiola, S., Alonso, J., Chatterji, S., Lee, S., Üstün, T. B., & Kessler, R. C. (2009) · Die Psychiatrie · doi:10.1055/s-0038-1671923 · Cited by 137
Altered anxiety and depression-related behaviour in mice lacking GABAB(2) receptor subunits
Mombereau, C., Kaupmann, K., Gassmann, M., Bettler, B., van der Putten, H., & Cryan, J. F. (2005) · Neuroreport · doi:10.1097/00001756-200502280-00021 · Cited by 135
Anxiety and increased 5-HT1A receptor response in NCAM null mutant mice
Stork, O., Welzl, H., Wotjak, C. T., Hoyer, D., Delling, M., Cremer, H., & Schachner, M. (1999) · Journal of Neurobiology · doi:10.1002/(sici)1097-4695(19990905)40:3<343::aid-neu6>3.0.co;2-s · Cited by 129
Encyclopedia of Psychopharmacology
Baumann, P. (2010) · Springer eBooks · doi:10.1007/978-3-642-27772-6 · Cited by 127
A new method for rapid screening of minor tranquillizers in mice
Boissier, J. R., Simon, P., & Aron, C. (1968) · European Journal of Pharmacology · doi:10.1016/0014-2999(68)90170-2 · Cited by 123
General and social anxiety in the BTBR T+ tf/J mouse strain
Pobbe, R. L. H., Defensor, E. B., Pearson, B. L., Bolivar, V. J., Blanchard, D. C., & Blanchard, R. J. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.08.039 · Cited by 122
Behavioral and neurochemical characterization of α2A-adrenergic receptor knockout mice
Lähdesmäki, J., Sallinen, J., MacDonald, E., Kobilka, B. K., Fagerholm, V., & Scheinin, M. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00185-9 · Cited by 119
Pharmacological Management of Treatment-Resistant Obsessive-Compulsive Disorder
Abudy, A., Juven‐Wetzler, A., & Zohar, J. (2011) · CNS Drugs · doi:10.2165/11587860-000000000-00000 · Cited by 118
Labrie, V., & Roder, J. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.08.002 · Cited by 118
Anxiety-like behavior in mice lacking the angiotensin II type-2 receptor
Okuyama, S., Sakagawa, T., Chaki, S., Imagawa, Y., Ichiki, T., & Inagami, T. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01098-7 · Cited by 116
The role of fragment-based and computational methods in polypharmacology
Bottegoni, G., Favia, A. D., Recanatini, M., & Cavalli, A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.08.002 · Cited by 116
Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mGlu8) receptor
Linden, A.-M., Johnson, B. G., Peters, S. C., Shannon, H. E., Tian, M., Wang, Y., Yu, J., Koster, A. M., Baez, M., & Schoepp, D. D. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00079-5 · Cited by 114
Bimodal Control of Fear-Coping Strategies by CB 1 Cannabinoid Receptors
Metna‐Laurent, M., Gómez, E. S., Verrier, D., Conforzi, M., Jégo, P., Lafenêtre, P., & Marsicano, G. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1054-12.2012 · Cited by 112
Holmes, A., & Quirk, G. (2009) · TIPS - Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.10.003 · Cited by 111
Self-citationKamprath, K., Plendl, W., Marsicano, G., Deussing, J. M., Wurst, W., Lutz, B., & Wotjak, C. T. (2008) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2008.00463.x · Cited by 110
Vinkers, C. H., van Bogaert, M. J. V., Klanker, M., Korte, S. M., Oosting, R. S., Hanania, T., Hopkins, S. C., Olivier, B., & Groenink, L. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.02.097 · Cited by 108
Bergado-Acosta, J. R., Sangha, S., Narayanan, R. T., Obata, K., Pape, H., & Stork, O. (2008) · Learning & Memory · doi:10.1101/lm.705408 · Cited by 107
Homanics, G. E., Harrison, N. L., Quinlan, J. J., Krasowski, M. D., Rick, C., Blas, A. L. D., Mehta, A. K., Kist, F., Mihalek, R., Aul, J. J., et al. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(98)00177-4 · Cited by 106
Bhatnagar, S., Sun, L. M., Raber, J., Maren, S., Julius, D. J., & Dallman, M. F. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.01.018 · Cited by 106
Heinrichs, S. C., Min, H., Tamraz, S., Carmouché, M., Boehme, S. A., & Vale, W. (1997) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(97)00030-9 · Cited by 106
Pharmacotherapy for posttraumatic stress disorder: Review with clinical applications
Jeffreys, M., Capehart, B. P., & Friedman, M. J. (2012) · The Journal of Rehabilitation Research and Development · doi:10.1682/jrrd.2011.09.0183 · Cited by 105
de Haas, S. L., de Visser, S. J., Post, J. P. V. D., Schoemaker, R. C., Dyck, K. V., Murphy, M. G., Smet, M. D., Vessey, L. K., Ramakrishnan, R., Xue, L., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107082108 · Cited by 105
Jacob, W., Yassouridis, A., Marsicano, G., Monory, K., Lutz, B., & Wotjak, C. T. (2009) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2009.00512.x · Cited by 105
Chrast, R. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.12.1853 · Cited by 104
Narayanan, V., Heiming, R. S., Jansen, F., Lesting, J., Sachser, N., Pape, H.-C., & Seidenbecher, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022600 · Cited by 103
Duvoisin, R. M., Zhang, C., Pfankuch, T. F., O'Connor, H., Gayet‐Primo, J., Quraishi, S., & Raber, J. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04210.x · Cited by 102
Sangha, S., Narayanan, R. T., Bergado-Acosta, J. R., Stork, O., Seidenbecher, T., & Pape, H. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.2620-09.2009 · Cited by 102
The infant rat separation paradigm: a novel test for novel anxiolytics
Winslow, J., & Insel, T. R. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90616-z · Cited by 102
Effects of Mild Early Life Stress on Abnormal Emotion-related Behaviors in 5-HTT Knockout Mice
Carroll, J. C., Boyce‐Rustay, J. M., Millstein, R. A., Yang, R. J., Wiedholz, L. M., Murphy, D. L., & Holmes, A. (2006) · Behavior Genetics · doi:10.1007/s10519-006-9129-9 · Cited by 98
Self-citationBehavioural validation of a light/dark choice procedure for testing anti-anxiety agents.
Misslin, R., Belzung, C., & Vogel, E. (1989) · Behavioural Processes · doi:10.1016/s0376-6357(89)80010-5 · Cited by 98
Frisch, C., Dere, E., Silva, M. A. D. S., Gödecke, A., Schrader, J., & Huston, J. P. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-17-06694.2000 · Cited by 96
Effect of Y1 receptor deficiency on motor activity, exploration, and anxiety
Karl, T., Burne, T. H. J., & Herzog, H. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.08.019 · Cited by 95
Kolber, B. J., Boyle, M. P., Wieczorek, L., Kelley, C. L., Onwuzurike, C., Nettles, S. A., Vogt, S. K., & Muglia, L. J. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.4470-09.2010 · Cited by 95
Pharmacological treatment of generalized anxiety disorder
Reinhold, J. A., Mandos, L. A., Rickels, K., & Lohoff, F. W. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.618496 · Cited by 95
McAuley, J. D., Stewart, A. L., Webber, E. S., Cromwell, H. C., Servatius, R. J., & Pang, K. C. H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.05.036 · Cited by 94
Painsipp, E., Herzog, H., Sperk, G., & Holzer, P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01326.x · Cited by 93
Goodfellow, N. M., Benekareddy, M., Vaidya, V. A., & Lambe, E. K. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1960-09.2009 · Cited by 92
The Gerbil Elevated Plus-Maze I Behavioral Characterization and Pharmacological Validation
Varty, G. B. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00312-3 · Cited by 87
de Haas, S. L., de Visser, S. J., van der Post, J. P., de Smet, M., Schoemaker, R. C., Rijnbeek, B., Cohen, A. F., Vega, J. M., Agrawal, N. G. B., Goel, T. V., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106072343 · Cited by 84
López-Aumatell, R., Vicens-Costa, E., Guitart‐Masip, M., Martínez-Membrives, E., Valdar, W. S. J., Johannesson, M., Cañete, T., Blázquez, G., Driscoll, P., Flint, J., et al. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.03.024 · Cited by 83
Rex, A., Marsden, C. A., & Fink, H. (1993) · Psychopharmacology · doi:10.1007/bf02244657 · Cited by 82
Wu, L., Ko, S. W., Toyoda, H., Zhao, M., Xu, H., Vadakkan, K. I., Ren, M., Knifed, E., Shum, F. W. F., Quan, J., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000167 · Cited by 81
Yilmazer‐Hanke, D., Faber‐Zuschratter, H., Linke, R., & Schwegler, H. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.01945.x · Cited by 81
Cited by
Using Neuroscience to Help Understand Fear and Anxiety: A Two-System Framework
LeDoux, J. E., & Pine, D. S. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16030353 · Cited by 1,035
Craske, M. G., Stein, M. B., Eley, T. C., Milad, M. R., Holmes, A., Rapee, R. M., & Wittchen, H.-U. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.24 · Cited by 652
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Meningeal γδ T cells regulate anxiety-like behavior via IL-17a signaling in neurons
Alves de Lima, K., Rustenhoven, J., Da Mesquita, S., Wall, M., Salvador, A. F., Smirnov, I., Martelossi Cebinelli, G., Mamuladze, T., Baker, W., Papadopoulos, Z., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0776-4 · Cited by 416
Singewald, N., Schmuckermair, C., Whittle, N., Holmes, A., & Ressler, K. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.004 · Cited by 390
“Various neuropeptides and their corresponding receptors are localized in brain regionsmediating emotional behavior and stress response and have been considered as potential anxiolytic drug targets (Bowers et al., 2012; Ebner et al., 2009; Griebel & Holmes, 2013).”
BackgroundSelf-citation
Metadata
- Authors
- Griebel, G., & Holmes, A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2013-08-30
- Volume
- 12
- Issue
- 9
- Pages
- 667-687
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1974420087
- Cited by
- 414
- References
- 284
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.